| ID | 1221 |
| Name of the vaccine | ETEC expressing CFA/I and CFA/II |
| Microbe | Bacteria |
| Disease name | E.coli Infections |
| Name of bacteria | Escherichia coli |
| Type of vaccine | Inactivated |
| Nucleic acid content | Circular duplex DNA |
| Age | NA |
| Description of the vaccine | Formalin-killed ETEC bacteria expressing CFA/I and CFA/II. |
| Name of the manufacturer | NA |
| Name of the manufacturing country | NA |
| Year of manufacture | NA |
| Clinical Phase status | Clinical |
| Bacterial strain | Gram-negative, rod-shaped bacteria. |
| Efficacy | 90% developed CFA-specific ASC responses after vaccination. |
| Vaccine formulation | NA |
| Dosage | Three doses, gap of 2 weeks. |
| Mechanism of action | IgA-ASCs and moderate CFA/I- and CFA/II-specific IgM-secreting ASC (IgM-ASC) responses. |
| Route of administration | Oral |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Cholera toxin B subunit |
| Repurposing | NA |
| Side effects of vaccine | Slight abdominal discomfort. |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=286&keywords= |
| Other name | NA |
| Additional Links | NA
|